2866179-95-3
Chemical Structure
Bleximenib oxalate
Synonym(s): JNJ-75276617 oxalate; Menin-MLL inhibitor 24 oxalate
- No. CAS: 2866179-95-3
- Formula:C34H52FN7O7
- Molecular Weight:689.82
InChIKey: OYKHOVACUSUKFI-HZPIKELBSA-N
SMILES: O=C(O)C(O)=O.COCCN(C)CCC[C@@H](N1CC2(C1)CN(C3=NC=NN=C3OC4=C(C=C(C=C4)F)C(N(CC)C(C)C)=O)CC2)C(C)C
Biological Activity: Bleximenib (JNJ-75276617) oxalate is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib oxalate can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib oxalate can be used in the research of tumors such as leukemia[1][2].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bleximenib oxalate | 98.09% | Bleximenib (JNJ-75276617) oxalate is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib oxalate can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib oxalate can be used in the research of tumors such as leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.93
HY-148669Bleximenib -
Similarity Score 0.93
HY-155797(S)-Bleximenib -
Similarity Score 0.89
HY-186043Menin-MLL-IN-35 -
Similarity Score 0.83
HY-186044Menin-MLL-IN-36 -
Similarity Score 0.54
HY-136175Revumenib -
Similarity Score 0.52
HY-114162RVTP50469 (Standard) -
Similarity Score 0.51
HY-114162BVTP50469 mesylate -
Similarity Score 0.49
HY-156794Enzomenib -
Similarity Score 0.49
HY-129167Menin-MLL inhibitor 4 -
Explore the MedChemAI to find more analogs
References
- [1]. Kwon MC, et al. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood. 2024 Sep 12;144(11):1206-1220. [Content Brief]
- [2]. Hogeling SM, et al. Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia. Haematologica. 2024 Dec 19. [Content Brief]
